Puma Biotechnology's closely watched neratinib failed to beat out the blockbuster Herceptin in a mid-stage breast cancer trial, a miss the company said was no surprise as it touted success on a secondary goal.
Investigators have hit on a potential target for triple-negative breast cancer, a disease that is notoriously impervious to some of the most effective therapies available for breast cancer and has attracted significant interest from drug developers.
Pharma companies are no stranger to photography-based disease awareness campaigns. But there's something different about AstraZeneca's latest breast cancer photo campaign: The photographers are the patients themselves.
Breast cancer detection may soon leave 2-D mammography in the dust, embracing instead a more comprehensive diagnostic tool: 3-D technology.
Researchers from the Nebraska Center for Materials and Nanoscience at the University of Nebraska have created a thin electronic skin made of nanoparticles and polymers that can be applied to the breast and used to find and image lumps.
A new breast cancer vaccine tested in a clinical trial at the University of Texas MD Anderson Cancer Center boosted survival rates in patients with elevated levels of a protein associated with cancer growth, a new study shows.
A researcher key in understanding the role the BRCA1 and BRCA2 genes play in breast and ovarian cancer, Mary-Claire King of the University of Washington, has called for women to be screened for these genes at around age 30 as part of routine care. Her latest research suggests that these genetic markers offer as much insight as a family cancer history into the risk faced by a particular woman.
As expected, Pfizer has submitted an early FDA application for palbociclib, beating a quick path to market with a breakthrough breast cancer treatment that could peak at nearly $3 billion a year.
Researchers in Chicago have developed a method by which to deliver a breast cancer-preventing drug through the skin to avoid some of the nasty side effects associated with oral ingestion of the drug.
Just a year after J&J swooped in to buy up Aragon's game-changing work on prostate cancer in a billion-dollar deal, Roche's Genentech has followed up to buy what remained: a closely-related breast cancer program that promises to change the way that disease is treated.